Developing cancer immunotherapies and combining immunotherapies has become even more difficult due to the hyper competitive nature of the space. Competition both within and between companies and academic institutions to develop the best candidates makes it challenging to navigate the field. IsoPlexis is helping leaders accelerate their workflows to provide the edge needed in this competitive atmosphere. Every advantage helps significantly in this field. One step in obtaining that competitive edge in the market is to accelerate workflows—don’t put your team at risk of falling behind while other researchers are adopting the best technologies.
CodePlex Offers a Faster and Completely Automated Approach to Bulk Cytokine Analysis
IsoPlexis is excited to announce the upcoming launch of a new family of products, CodePlex, which runs on the award-winning IsoLight system. We are taking all of the steps and included instrumentation, from washing, staining, spinning, vortexing, as well as incubating and reading your samples on a plate reader, and completely automating them into one system. Just add your sample and walk away, achieving fully analyzed data on the same day. Starting with the Population Immuno-Oncology Cytokine solution, the CodePlex family of chips is helping researchers by:
- Providing a fully automated end-to-end workflow, meaning only five minutes of hands-on time
- CodePlex only requires sample loading versus the multi-step process required on existing platforms and enables 20x faster data at the population level compared to existing protein multiplexing systems
- Multiplexing to 30+ cytokines
- Offering a modular solution to look at as low as 8 samples at a time, up to 64 samples, instead of needing a full 96 samples before generating multiplexed bulk cytokine data
- Automatically analyzing the data
- Running on the IsoLight as a proteomic hub
The IsoLight platform with the CodePlex family of chips offers vast improvements over currently available bulk platforms from uniquely capturing key measures of multiplexed bulk cytokine metrics to comprehensive functional profiling of each single cell across a large assay menu of single cell chip and software products. As with our IsoCode Chips, the CodePlex Chip can run T cells of various subtypes, NK cells, monocytes, and more. The CodePlex family of chips can also generate data in a matter of hours versus the days required by other population assays and helps researchers optimize their workflow with a completely automated approach. With only five minutes of direct loading time, researchers can walk away from the experiment and come back the same day with fully analyzed data, completely speeding up their entire workflow.
This population based CodePlex Chip can be used to generate multiplexed serum level data as well as optimize experimental conditions quickly and in a cost-efficient manner. These chips measure the 32+ cytokines in bulk, automated on the integrated IsoLight system. After gaining the population proteomic information from a sample and optimizing conditions, the single-cell chip solutions and panels offered by IsoPlexis, also run on the IsoLight system, cover almost any cell type to help complete the functional phenotyping of a cell sample. With more panels on the way, IsoPlexis’ proteomic hub can help streamline processes while providing the necessary data to accelerate workflows and the development of therapies.
How Researchers Have Applied CodePlex to Gain Insight into Their Samples
Cancer cells in the tumor microenvironment secrete cytokines that interact with other cells, such as immune cells, in a 3D extracellular matrix, which facilitates intercellular communications and jointly moderate pathophysiological processes, “including cancer-induced angiogenesis and metastasis.”1 Secretomic profiles of cancer cells advance as they multiply and become more invasive, which suggests that secreted factors may be associated with proliferation and migration. Researchers in one study, published in Nature Communications, speculated that the involvement of proliferation-induced local gathering and the increased local cell density of the 3D tumor microenvironment could be significant, but that there were unidentified factors directly changing tumor cell migration.
These researchers utilized IsoPlexis’ technology to gain insight into whether soluble molecules secreted by cells were responsible for controlling the cell-density-dependent migration. Researchers discovered that the soluble molecules secreted by the matrix embedded cancer cells were adequate in promoting improved cell migration. They then used CodePlex to identify what soluble factor or factors were driving increased mobility by measuring and analyzing the secretomic profiles of the HT1080 and MDA-MB-321 cells ingrained in 3D matrices at both low and high densities with a multiplex antibody microarray assay, which simultaneously measured the concentration of 24 soluble molecules. Both cytokines IL-6 and IL-8 were secreted at high concentrations in a specific ratio, while proteins typically associated with promoting tumor metastasis and progression were not elevated, suggesting that both of these cytokines are responsible for driving the density-dependent cell migration within 3D matrices. Overall, this study discovered a possible mechanism promoting tumor cell migration while inferring an approach to reduce metastatic capability of tumor cells.
IsoPlexis’ Platform Enables an Automated End-to-End Workflow
Our IsoSpeak software family provides an application suite supporting each of our chips. This creates an innovation and impactful end-to-end workflow and application for almost every key cell type, from early optimization to applying key, correlative insights and visualizations. Many researchers need to run both single-cell and population cytokine assays, so rather than purchasing multiple systems that require lots of space and time to run, the IsoLight system serves as a proteomic hub that can automatically run both of these assays much faster and more efficiently than other systems currently available.
Interested in using the IsoLight as a hub for both single cell and population proteomic analysis? The new CodePlex chip will run the Population Immuno-Oncology Cytokine (human) application and will be available for purchase in March of 2020. Check out the product sheet here for more details on this new technology.
- Jayatilaka H, et al. Synergistic IL-6 and IL-8 paracrine signalling pathway infers a strategy to inhibit tumour cell migration. Nature Communications 8: 15584, 2017.